Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3. (Q38134774)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24010641%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

title

Is 3 the new 1: perspectives on virology, natural history and treatment for hepatitis C genotype 3 (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24010641%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

0 references

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24010641%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

E B Tapper

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24010641%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

language of work or name

1 reference

1 October 2013

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24010641%20AND%20SRC:MED&resulttype=core&format=json

Journal of Viral Hepatitis

20 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24010641%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24010641%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24010641%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

669-677

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24010641%20AND%20SRC:MED&resulttype=core&format=json

Global burden of disease (GBD) for hepatitis C.

20 February 2020

cites work

1 reference

A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel

21 January 2018

1 reference

Sofosbuvir for previously untreated chronic hepatitis C infection

21 January 2018

1 reference

Hepatitis C therapy in non-genotype 1 patients: the near future

21 January 2018

1 reference

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

21 January 2018

1 reference

A proposed system for the nomenclature of hepatitis C viral genotypes

21 January 2018

1 reference

Clinical significance of hepatitis C virus genotypes

21 January 2018

1 reference

Full-length sequence of a hepatitis C virus genome having poor homology to reported isolates: comparative study of four distinct genotypes

21 January 2018

1 reference

The epidemic behavior of the hepatitis C virus

21 January 2018

1 reference

The epidemiology and iatrogenic transmission of hepatitis C virus in Egypt: a Bayesian coalescent approach

21 January 2018

1 reference

Hepatitis C virus genotype 3 predominates in North and Central India and is associated with significant histopathologic liver disease

21 January 2018

1 reference

Global epidemiology of hepatitis C virus infection

21 January 2018

1 reference

Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor

21 January 2018

1 reference

Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins

21 January 2018

1 reference

Hepatitis C virus core protein inhibits microsomal triglyceride transfer protein activity and very low density lipoprotein secretion: a model of viral-related steatosis

21 January 2018

1 reference

Hepatitis C virus core protein induces hepatic steatosis in transgenic mice

21 January 2018

1 reference

Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core

21 January 2018

1 reference

An in vitro model of hepatitis C virus genotype 3a-associated triglycerides accumulation

21 January 2018

1 reference

Genotype-specific mechanisms for hepatic steatosis in chronic hepatitis C infection.

21 January 2018

1 reference

Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C.

21 January 2018

1 reference

Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up

21 January 2018

1 reference

Hepatitis C virus selectively perturbs the distal cholesterol synthesis pathway in a genotype-specific manner

21 January 2018

1 reference

Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection

21 January 2018

1 reference

Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy

21 January 2018

1 reference

Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3.

21 January 2018

1 reference

Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity

21 January 2018

1 reference

Different mechanisms of steatosis in hepatitis C virus genotypes 1 and 3 infections

21 January 2018

1 reference

Steatosis accelerates fibrosis development over time in hepatitis C virus genotype 3 infected patients

21 January 2018

1 reference

Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response

21 January 2018

1 reference

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

Genotype 3 is associated with accelerated fibrosis progression in chronic hepatitis C.

21 January 2018

1 reference

Natural history and predictors of disease severity in chronic hepatitis C.

21 January 2018

1 reference

Relationship between steatosis, inflammation, and fibrosis in chronic hepatitis C: a meta-analysis of individual patient data.

21 January 2018

1 reference

HCV genotype 3 is associated with a higher hepatocellular carcinoma incidence in patients with ongoing viral C cirrhosis

21 January 2018

1 reference

Hepatocellular carcinoma: epidemiology and molecular carcinogenesis

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Pegylated interferon alfa and ribavirin for 14 versus 24 weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response

21 January 2018

1 reference

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

21 January 2018

1 reference

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

21 January 2018

1 reference

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial

21 January 2018

1 reference

Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection

21 January 2018

1 reference

Reduced dose and duration of peginterferon alfa-2b and weight-based ribavirin in patients with genotype 2 and 3 chronic hepatitis C.

21 January 2018

1 reference

Update on the treatment of patients with non-genotype 1 hepatitis C virus infection

21 January 2018

1 reference

Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin

21 January 2018

1 reference

Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3.

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

Peginterferon and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

EASL Clinical Practice Guidelines: management of hepatitis C virus infection

21 January 2018

1 reference

Clinical utility of interleukin-28B testing in patients with genotype 1.

21 January 2018

1 reference

IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection

21 January 2018

1 reference

Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients

21 January 2018

1 reference

An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response

21 January 2018

1 reference

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections

21 January 2018

1 reference

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

21 January 2018

1 reference

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/JVH.12168

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24010641%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference